Sanofi and AZ’s RSV Antibody Gets EU Thumbs Up But Pfizer Rival Hot On Heels
Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.
You may also be interested in...
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.
Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.